ArticleCancer immunology, immunotherapy : CII2026
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).
Stefanie Zschäbitz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.